Association of Normal-Weight Central Obesity With All-Cause and Cause-Specific Mortality Among Postmenopausal Women

Key Points Question How is normal-weight central obesity associated with risk of mortality compared with other anthropometric phenotypes? Findings In this cohort study of 156 624 postmenopausal US women enrolled in the Women’s Health Initiative study, normal-weight central obesity was associated with higher risk of all-cause, cardiovascular disease, and cancer mortality compared with normal weight without central obesity. The magnitude of this association was similar to that of obesity with central obesity and higher than that of other anthropometric phenotypes defined by body mass index and waist circumference. Meaning Normal-weight central obesity is an underrecognized, high-risk phenotype for mortality.

[1]  C. Quesenberry,et al.  Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer , 2018, JAMA oncology.

[2]  B. Caan,et al.  The Importance of Body Composition in Explaining the Overweight Paradox in Cancer-Counterpoint. , 2018, Cancer research.

[3]  Yiqing Song,et al.  Associations of Muscle Mass and Strength with All-Cause Mortality among US Older Adults , 2017, Medicine and science in sports and exercise.

[4]  Tao He,et al.  Abdominal obesity and colorectal cancer risk: systematic review and meta-analysis of prospective studies , 2017, Bioscience reports.

[5]  Chengcheng Hu,et al.  Body Mass Index, Waist Circumference, and Mortality in a Large Multiethnic Postmenopausal Cohort—Results from the Women's Health Initiative , 2017, Journal of the American Geriatrics Society.

[6]  E. Stamatakis,et al.  Normal-Weight Central Obesity and Risk for Mortality , 2017, Annals of Internal Medicine.

[7]  J. Meyerhardt,et al.  Explaining the Obesity Paradox: The Association between Body Composition and Colorectal Cancer Survival (C-SCANS Study) , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[8]  S. Anton,et al.  Prevalence of Prediabetes and Abdominal Obesity Among Healthy-Weight Adults: 18-Year Trend , 2016, The Annals of Family Medicine.

[9]  I. Janszky,et al.  BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants , 2016, British Medical Journal.

[10]  S. Vedal,et al.  Individual and Neighborhood Socioeconomic Status and the Association between Air Pollution and Cardiovascular Disease , 2016, Environmental health perspectives.

[11]  C. Tseng,et al.  Relation of Muscle Mass and Fat Mass to Cardiovascular Disease Mortality. , 2016, The American journal of cardiology.

[12]  C. Lewis,et al.  Body shape, adiposity index, and mortality in postmenopausal women: Findings from the Women's Health Initiative , 2016, Obesity.

[13]  M. Jensen,et al.  Normal-Weight Central Obesity: Implications for Total and Cardiovascular Mortality , 2015, Annals of Internal Medicine.

[14]  C. Lewis,et al.  Risk of Mortality According to Body Mass Index and Body Composition Among Postmenopausal Women. , 2015, American journal of epidemiology.

[15]  A. Karlamangla,et al.  Muscle mass index as a predictor of longevity in older adults. , 2014, The American journal of medicine.

[16]  S. Blair,et al.  Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox. , 2014, Journal of the American College of Cardiology.

[17]  Olia Papacosta,et al.  The obesity paradox in men with coronary heart disease and heart failure: The role of muscle mass and leptin , 2014, International journal of cardiology.

[18]  F. Hu,et al.  2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. , 2014, Journal of the American College of Cardiology.

[19]  Ross Arena,et al.  Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. , 2013, JACC. Heart failure.

[20]  K. Flegal,et al.  Association of All-Cause Mortality With Overweight and Obesity Using Standard Body Mass Index Categories , 2012 .

[21]  Antonio Brunetti,et al.  Insulin Resistance and Cancer Risk: An Overview of the Pathogenetic Mechanisms , 2012, Experimental diabetes research.

[22]  E. Rimm,et al.  Alternative dietary indices both strongly predict risk of chronic disease. , 2012, The Journal of nutrition.

[23]  Y Schutz,et al.  Body composition phenotypes in pathways to obesity and the metabolic syndrome , 2010, International Journal of Obesity.

[24]  F. Karpe,et al.  Gluteofemoral body fat as a determinant of metabolic health , 2010, International Journal of Obesity.

[25]  Frank B. Hu,et al.  Abdominal Obesity and the Risk of All-Cause, Cardiovascular, and Cancer Mortality: Sixteen Years of Follow-Up in US Women , 2008, Circulation.

[26]  C. Rock,et al.  Validation of the WHI brief physical activity questionnaire among women diagnosed with breast cancer. , 2007, American journal of health behavior.

[27]  J. Després,et al.  Intra-abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular disease. , 2006, Journal of endocrinological investigation.

[28]  Fernando Costa,et al.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.

[29]  G. Anantharamaiah,et al.  The role of high-density lipoprotein in inflammation. , 2005, Trends in cardiovascular medicine.

[30]  C. Kooperberg,et al.  Outcomes ascertainment and adjudication methods in the Women's Health Initiative. , 2003, Annals of epidemiology.

[31]  A. Howell,et al.  Central obesity and breast cancer risk: a systematic review , 2003, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[32]  JoAnn E. Manson,et al.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. , 1998, Controlled clinical trials.